Skip to content

Use of two different Ayurvedic compound formulation in Shwasa Roga (Bronchial Asthma)

Safety and Efficacy study of Mallasindura prepared by two different methods w.s.r. to Tamaka Swasa (Bronchial asthma)

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/08/006141
Enrollment
60
Registered
2015-08-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J453- Mild persistent asthma Health Condition 2: null- Tamaka Swasa (Bronchial Asthma)

Interventions

Intervention1: Mallasindura with Rasakarpura (MSRK): 62 mg of drug will be given orally twice a day with honey for 28 days after koshta shudhi by Erandbhrishta Haritaki churna 3 gm orally with lukewar

Sponsors

IPGTRA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients having classical signs and symptoms of Tamaka Swasa like breathlessness, wheeze etc.Mild persistent cases of Asthma (as per WHO GINA Guideline) of duration more than 6 months.Symptoms/exacerbation (Wheeze, cough and breathlessness) greater than weekly and less than daily in frequency.Night symptoms twice per month but less than once a week.

Exclusion criteria

Exclusion criteria: Age more than 60 years and below 16 years.Mild intermittent, Moderated persistent, severe persistent to severe Asthma.Dyspnoea resulting from other diseases like left ventricular failure, COPD (Chronic Bronchitis, Emphysema), upper respiratory tract obstruction, bronchiectasis, cases of tuberculosis, interstitial lung disease/occupational lung disease, tropical pulmonary eosinophilia & allergic bronchopulmonary aspergillosis etc. Patients having anaemia, pneumonia, tuberculosis, lung cancer, lung abscess and other such complicated conditions. Patients having diabetes, hypertension, Chronic and Acute renal failure etc. conditions in which urination is markedly diminished or excessive were excluded. HIV positive cases. Pregnant/lactating mother. Patients who need Salbutamol inhaler daily. Patients having classical symptoms of Maha, Urdha, Chhinna and Kshudra Shwasa.

Design outcomes

Primary

MeasureTime frame
Changes in clinical symptoms of Asthma like breathlessness cough wheezing etc Per week frequency of asthmatic attacks before and after treatment PEFR AEC other laboratory investigations will be observed before and after treatmentTimepoint: 4 weeks

Secondary

MeasureTime frame
Changes in Asthma control questionnarieTimepoint: at time interval of 28 days

Countries

India

Contacts

Public ContactDr BJ Patgiri

Department of RSBK IPGTRA Gujarat Ayurved University Jamnagar

patgiri06@yahoo.co.in9426947438

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026